Immuron Ltd — Capital/Financing Update 2011

Mar 16, 2011

==> picture [193 x 42] intentionally omitted <==

ASX Release

17 MARCH 2011

Immuron Limited ABN 80 063 114 045

IMMURON’S INFLUENZA PROGRAM SHOWS EFFECTIVENESS

Corporate Details:

 This program will potentially produce the world’s first orally administered product for mucosal protection against Influenza virus

ASX Code: IMC

Directors

 Immuron’s Board approves the next stage of development of its Influenza candidate.

Chairman:

Prof. Colin Chapman Non-Executive Directors: Prof. Roy Robins-Browne Mr Simon Sallka Dr Elane Zelcer

Chief Executive Officer Joe Baini

Chief Scientific Officer Dr Grant Rawlin

Medical Director Prof. Yaron Ilan

Substantial Shareholder

Hadasit Medical Research 17.9%

Contact Details:

Immuron Limited Level 1 39 Leveson Street North Melbourne VIC 3051 Australia

Results of preliminary experiments indicate that Immuron’s influenza candidate is effective in ferrets. These findings are highly encouraging and indicate the need for further experiments to support these results and extend them to more prevalent strains of influenza virus.

Ferrets are used as the “gold standard” in experiments of human influenza because they are naturally susceptible to the human influenza virus. The aim of the research was to identify the protective action of Immuron’s antibodies against infection with H1N1 human virus isolates.

“Our aim is pursue the lucrative large market opportunity of influenza prevention. The Board has decided to proceed to further testing in ferrets, aiming to confirm these results, which should inform the design for future human trials. Our commitment is based on internal confidence and strong encouragement from eminent medical researchers in infectious diseases”, said Mr Joe Baini, CEO of Immuron.

In parallel to the above work being conducted with the University of Melbourne, Immuron’s research team at Hadassah Medical Center in Jerusalem has investigated the effect on the cell-mediated immune system when mice are fed anti-influenza antibodies to further define mechanisms of action. This led to improved cell activation against several strains of influenza virus. Further animal studies at the University of Melbourne in support of the work at Hadassah are planned to commence in Q2 of 2011. The initial work with mice has been published recently in the peer reviewed Public Library of Science One Journal.

The safety profile associated with the Immuron platform technology suggests the ability to accelerate product to market.

ENDS

Tel: +61 (0)3 8637 1107 www.immuron.com

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited.

Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as type II diabetes and fatty liver (NASH), and the prevention of influenza.

Immuron has one product in the market, Travelan, for use in preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and the Universities of Melbourne and Monash (Australia).

For more information please contact:

Joe Baini – Chief Executive Officer Immuron Ltd Tel: +61 3 8637 1107 Email: joe@immuron.com

Media Relations:

Emma Power Monsoon Communications Tel: 61 3 9620 3333 or 61 (0)419 149 525